The deal size was increased to $125M in common stock from $100M in common stock. Goldman Sachs, BofA, Barclays and Oppenheimer acted as joint ...

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public ...

Tarsus Pharmaceuticals (NASDAQ:TARS) priced an upsized underwritten public offering of 2.81M shares of its common stock at a public offering price of $44.50 per share. Underwriters have a 30-day ...

The Irvine-based biopharmaceutical company today announced the underwritten public offering after market close today.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given an average recommendation of “Buy” by the seven ...

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03 ...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the ...

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of ...

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public ...